ABT
Wall Street’s gentle slap on the wrist
Abbott just got the kind of note investors dread: a price-target cut dressed up with a thumbs-up. TD Cowen dropped its target on ABT to $115 from $137, but kept a Buy rating, which is basically Wall Street saying, “We’re still invited to the party, we’re just less excited about the appetizers.”
Why the temperature changed
The firm pointed to Abbott’s lower organic guidance and some softness in respiratory and Libre products during the first quarter. That matters because when a company’s forecast gets trimmed, the market tends to squint at the whole story — even if the underlying business isn’t suddenly falling apart.
The stock reacted exactly how you’d expect
Abbott shares slid 6% on the day of the announcement. That’s a pretty loud reaction for what’s technically still a positive rating, but investors were already digesting the company’s softer outlook and the broader mix of earnings-related updates.
Still not throwing the baby out with the bathwater
TD Cowen said it remains constructive on Abbott and still sees value in the shares at current levels. Translation: the analyst isn’t calling the ship sunk, just admitting the cruise got a little bumpier than expected.
Big picture: this is less a disaster and more a valuation-versus-growth reality check. If Abbott can steady its guidance and get its key product lines back in gear, the “still likes it” crowd may get the last laugh.